Durabolin25 mg/ml

Durabolin is a synthetic anabolic-androgenic steroid (an ester of nandrolone) used, under specialist medical supervision, for a limited number of established clinical indications:

• Certain anemias: As an adjunctive therapy to help stimulate erythropoiesis in selected anemias, including anemia associated with chronic renal insufficiency and other refractory anemias, when used together with appropriate primary treatment (e.g., correction of the underlying cause, iron supplementation, or erythropoiesis-stimulating agents where indicated).
• Cachexia and wasting states: As an adjunct to help improve nitrogen balance, appetite, and lean body mass in catabolic conditions such as chronic wasting illness, prolonged corticosteroid therapy, or severe debilitation, when used as part of a broader nutritional and medical treatment plan.
• Osteoporosis: As an adjunctive agent in the management of osteoporosis in specific clinical contexts (e.g., postmenopausal osteoporosis), typically alongside calcium, vitamin D, and other standard osteoporosis therapies, and only when first-line agents are unsuitable or insufficient.

Durabolin has no approved indication for enhancing athletic performance or physique, and such non-medical use is not supported by evidence and carries significant health risks.

Each ampoule/vial for intramuscular injection contains Nandrolone Phenylpropionate as the active ingredient in an oily (e.g., arachis/sesame oil) vehicle for intramuscular injection, commonly available in a 25 mg/mL strength.

Durabolin is a synthetic derivative of testosterone, classified as an anabolic-androgenic steroid (AAS). It is an ester of the parent compound nandrolone, formulated for intramuscular injection in an oily vehicle to provide a relatively short duration of action (typically requiring more frequent dosing than the decanoate ester).

Durabolin exhibits pronounced anabolic (tissue-building) activity with comparatively lower androgenic activity relative to testosterone, which underlies its historical use in catabolic and wasting conditions. It is a controlled/regulated substance in many jurisdictions due to its recognized potential for misuse in non-medical performance and physique enhancement.

Durabolin belongs to the therapeutic class of Anabolic Androgenic Steroids (AAS), a subclass of sex hormones and their synthetic derivatives.

Nandrolone Phenylpropionate binds to androgen receptors in target tissues (muscle, bone, bone marrow, and others), producing both anabolic (protein-synthesis-promoting, nitrogen-retaining) and androgenic (masculinizing) effects. Its anabolic-to-androgenic activity ratio is more favorable toward anabolic effects compared with testosterone itself, though androgenic effects still occur, particularly at higher doses or with prolonged use.

Mechanistically, Nandrolone Phenylpropionate promotes erythropoiesis by stimulating renal erythropoietin production and directly stimulating bone marrow erythroid progenitor cells. It also promotes positive nitrogen balance and protein anabolism in skeletal muscle, and stimulates osteoblastic activity contributing to increased bone mineral density.

After intramuscular injection, the phenylpropionate ester is slowly hydrolyzed to release free nandrolone, which is then metabolized primarily in the liver and excreted mainly in urine as metabolites. The phenylpropionate ester has a shorter duration of action (requiring dosing roughly every 1-2 weeks) compared with the longer-acting decanoate ester.

Durabolin is administered by deep intramuscular injection only (e.g., into the gluteal muscle), by or under the supervision of a trained healthcare professional. It must not be given intravenously or subcutaneously. Injection sites should be rotated, and the vial should be inspected visually for particulate matter or discoloration before use.

Durabolin has the following clinically significant drug interactions:

• Oral anticoagulants (e.g., warfarin): Durabolin may enhance anticoagulant effect by altering clotting factor synthesis and reducing anticoagulant-binding proteins, increasing bleeding risk. Anticoagulant dose adjustment and closer INR monitoring may be required.
• Antidiabetic agents (insulin, oral hypoglycemics): Durabolin may improve glucose tolerance and reduce insulin/antidiabetic drug requirements; blood glucose should be monitored and doses adjusted as needed.
• Hepatotoxic drugs: Concomitant use with other potentially hepatotoxic medications may increase the risk of liver injury; liver function should be monitored.
• Corticosteroids/ACTH: Concurrent use with Durabolin may increase the risk of fluid retention and edema; caution is advised, particularly in patients with cardiac or renal disease.

Adverse effects of Durabolin are generally dose- and duration-related. Commonly reported effects include:

• Virilization (in women): voice deepening, hirsutism, acne, clitoral enlargement, menstrual irregularities - some of these effects may be irreversible even after stopping treatment.
• Hepatic effects: abnormal liver function tests, cholestatic jaundice, and, rarely, hepatic tumors or peliosis hepatis with prolonged use (see Precautions and Warnings).
• Cardiovascular/metabolic: fluid and sodium retention, edema, and adverse changes in lipid profile (decreased HDL, increased LDL).
• Endocrine: suppression of endogenous testosterone production and spermatogenesis, gynecomastia, testicular atrophy in men.
• Other: acne, increased libido or, less commonly, decreased libido, injection site pain/induration, and, in adolescents, premature closure of bone growth plates.

Durabolin is contraindicated in pregnancy because of the risk of virilization of a female fetus; it should not be used by pregnant women under any circumstances.

It is not recommended during breastfeeding, as androgens can be excreted in breast milk and may affect the nursing infant (including potential effects on infant growth and development); an alternative should be used, or breastfeeding should be discontinued if therapy is unavoidable, only after consulting a physician.

Use Durabolin only under specialist medical supervision, with attention to the following precautions:

• Hepatotoxicity: Prolonged use has been associated with liver function abnormalities and, rarely, peliosis hepatis or hepatic neoplasms; periodic liver function monitoring is recommended, particularly with long-term therapy.
• Cardiovascular risk: May cause fluid retention and unfavorable changes in lipid profile; use with caution in patients with cardiac, renal, or hepatic disease, and in those with conditions worsened by fluid retention (e.g., epilepsy, migraine).
• Virilization: Women should be monitored closely for signs of virilization; discontinue promptly if these occur, as some effects may not be reversible.
• Endocrine suppression: May suppress endogenous testosterone production and spermatogenesis with prolonged use; effects on fertility should be discussed with patients.
• Adolescents: May accelerate bone maturation and cause premature closure of epiphyseal growth plates if used before growth is complete; bone age should be monitored (see Use in Special Populations).
• Hypercalcemia: May cause or worsen hypercalcemia, particularly in patients with breast cancer or those who are immobilized; calcium levels should be monitored.
• Regulatory status: Durabolin is a controlled/regulated substance in many countries due to its potential for non-medical misuse; it should be used strictly as prescribed and not shared with others.

There is limited clinical data on acute overdose with Durabolin, as it is administered by injection under medical supervision. Suspected overdose or significant adverse symptoms following administration should be treated as a medical emergency: seek immediate medical attention or contact a poison control center/emergency services promptly. Management is supportive and symptomatic, based on the presenting features, and should be carried out by qualified medical personnel.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep out of reach of children.

• Pediatric use: Durabolin may be used in specific pediatric conditions only under pediatric endocrinology/specialist supervision, with careful monitoring of bone age (radiographs every 6 months) due to the risk of premature epiphyseal closure and compromised final adult height; safety and efficacy for routine pediatric use are not well established, and use in adolescents before growth completion requires particular caution.
• Elderly: Use with caution; elderly men, particularly those with occult prostate cancer, may be at increased risk of prostatic hyperplasia or malignancy; periodic prostate monitoring is advised.
• Renal impairment: May be used as adjunctive therapy for anemia of renal insufficiency, but should be used cautiously in patients with significant renal disease due to fluid retention risk; contraindicated in nephrosis/nephrotic phase of nephritis.
• Hepatic impairment: Contraindicated in severe hepatic impairment; use with caution and close monitoring in mild-to-moderate hepatic disease.
• Women: Increased risk of virilization; use only when benefits clearly outweigh risks, with close monitoring.

Duration of treatment with Durabolin should be determined by the prescribing physician based on indication and clinical response, and is generally kept as short as possible with periodic reassessment (e.g., every few months) to weigh continued benefit against cumulative risks such as hepatotoxicity and virilization.

Anabolic Androgenic Steroids

Nandrolone Phenylpropionate acts by binding to androgen receptors, promoting protein anabolism, nitrogen retention, and erythropoiesis, while also exerting androgenic effects on secondary sexual characteristics.

Use of Durabolin in children and adolescents is restricted to specific specialist-supervised indications and requires careful monitoring of bone age and growth due to the risk of premature epiphyseal closure; routine or non-medical use in minors is not supported and safety/efficacy outside specialist-directed indications is not established.